In conclusion, correlation analysis of data from the HATFF study indicates that the responses of optimised Glo1 inducer, tRES-HESP, are linked to improvements in dysglycemia, blood pressure, dyslipidemia, and low-grade inflammation. This evidence concerns the gene GLO1 and metabolic syndrome.